Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06517641 · ClinicalTrials.gov registry record · Phase 2
Clinical Trial of Upfront Haploidentical or Unrelated Donor BMT to Restore Normal Hematopoiesis in Aplastic Anemia
A Phase 2 study of Severe Aplastic Anemia, sponsored by Medical College of Wisconsin.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 60
- Enrollment target
- 20
- Study locations
NCT06517641 is a Phase 2 study of Severe Aplastic Anemia that is actively recruiting participants, run by Medical College of Wisconsin. The registered enrollment target is 60 participants, below the 123-participant average among 16 other Severe Aplastic Anemia trials with a reported enrollment target (51% lower). The trial reports 20 study locations across 14 states.
The verdict
NCT06517641, a Phase 2 study of Severe Aplastic Anemia, is actively recruiting participants, sponsored by Medical College of Wisconsin.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 60 participants
- Enrollment target
- 20
- Study locations
Study Summary
BMT CTN 2207 will investigate the use of marrow transplantation for treatment of severe aplastic anemia that has not previously been treated.
Conditions Studied
Interventions
- DRUG Haploidentical donor bone marrow transplant
- DRUG Unrelated donor bone marrow transplant
Study Locations (20)
California
- City of Hope - Duarte
- University of California, Los Angeles - Los Angeles
- Stanford University - Stanford
North Carolina
- UNC Chapel Hill - Chapel Hill
- Levine Cancer Institute - Charlotte
- Duke University Health System - Durham
Georgia
- Emory Winship Cancer Institute - Atlanta
- Blood and Marrow Transplant Center at Northside Hospital - Atlanta
Massachusetts
- Massachusetts General Hospital - Boston
- Dana Farber Cancer Institute - Boston
Alabama
- University of Alabama at Birmingham - Birmingham
Florida
- Moffitt Cancer Center - Tampa
Kansas
- University of Kansas Medical Center - Westwood
Maryland
- Johns Hopkins University - Baltimore
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2025-05-12 |
| Est. Completion | 2029-02-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06517641
The ClinicalTrials.gov registry entry for NCT06517641 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 60 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 123-participant average among 16 other Severe Aplastic Anemia trials with a reported enrollment target (51% lower). The listed sponsor is Medical College of Wisconsin, which has 447 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Severe Aplastic Anemia appearing as the primary indexed condition, and to 2 interventions - of which Haploidentical donor bone marrow transplant is the first listed.
NCT06517641 reports 20 study locations spanning 14 distinct geographic areas - top geographies include California, North Carolina, Georgia.
Frequently Asked Questions
What is clinical trial NCT06517641 about?
NCT06517641 is a clinical study titled "Clinical Trial of Upfront Haploidentical or Unrelated Donor BMT to Restore Normal Hematopoiesis in Aplastic Anemia". BMT CTN 2207 will investigate the use of marrow transplantation for treatment of severe aplastic anemia that has not previously been treated.
What is the current status of trial NCT06517641?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 60 participants. The study started on 2025-05-12. Estimated completion is 2029-02-01.
What conditions does trial NCT06517641 study?
This clinical trial studies the following conditions: Severe Aplastic Anemia.
What interventions are being tested in trial NCT06517641?
The interventions under investigation include: Haploidentical donor bone marrow transplant (DRUG), Unrelated donor bone marrow transplant (DRUG).
Who is sponsoring clinical trial NCT06517641?
This trial is sponsored by Medical College of Wisconsin, which has 447 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06517641 being conducted?
This trial has 20 study locations across Alabama, California, Florida, Georgia, Kansas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Severe Aplastic Anemia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Early Initiation of Oral Therapy With Cyclosporine and Eltrombopag for Treatment Naive Severe Aplastic Anemia (SAA)
RECRUITING · Phase 2
-
Allogeneic Hematopoietic Stem Cell Transplantation for Severe Aplastic Anemia and Other Bone Marrow Failure Syndromes Using G-CSF Mobilized CD34+ Selected Hematopoietic Precursor Cells Co-Infused With a Reduced Dose of Non-Mobilized Donor T-cells
RECRUITING · Phase 2
-
TCR Alpha Beta T-cell Depleted Haploidentical HCT in the Treatment of Non-Malignant Hematological Disorders in Children
RECRUITING · Phase 2
-
Haploidentical Bone Marrow Transplant With Post-Transplant Cyclophosphamide for Patients With Severe Aplastic Anemia
RECRUITING · Phase 2
-
Alpha/Beta TCD HCT in Patients With Inherited BMF Disorders
RECRUITING · Phase 2
-
AlloSCT for Malignant and Non-malignant Hematologic Diseases Utilizing Alpha/Beta T Cell and CD19+ B Cell Depletion
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.